MAGUK proteins: New targets for pharmacological intervention in the glutamatergic synapse

European Journal of Pharmacology

Volumn 585, Issue 1, 2008, Pages 147-152

  Gardoni, Fabrizio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Glutamate; Neurodegenerative disorders; Postsynaptic density; Scaffolding proteins

Indexed keywords

LEVODOPA; MEMBRANE ASSOCIATED GUANYLATE CYCLASE KINASE; N METHYL DEXTRO ASPARTIC ACID; POSTSYNAPTIC DENSITY PROTEIN 95;

ALZHEIMER DISEASE; BRAIN INJURY; CHRONIC PAIN; DEGENERATIVE DISEASE; DYSKINESIA; HUMAN; HUNTINGTON CHOREA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SYNAPSE;

ALZHEIMER DISEASE; ANIMALS; ANTIPARKINSON AGENTS; CHRONIC DISEASE; DYSKINESIA, DRUG-INDUCED; GLUTAMIC ACID; GUANYLATE KINASE; HUMANS; HUNTINGTON DISEASE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEVODOPA; MEMBRANE PROTEINS; PAIN; PROTEIN SUBUNITS; RECEPTORS, N-METHYL-D-ASPARTATE; STROKE; SYNAPSES;

EID: 42249114000     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.01.048     Document Type: Review

References (50)

1. Aarts M., Liu Y., Liu L., Besshoh S., Arundine M., Gurd J.W., Wang Y.T., Salter M.W., and Tymianski M. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 298 (2002) 846-850
2. Bertoni-Freddari C., Fattoretti P., Casoli T., Caselli U., and Meier-Ruge W. Deterioration threshold of synaptic morphology in aging and senile dementia of Alzheimer's type. Anal. Quant. Cytol. Histol. 18 (1996) 209-213
3. Calabresi P., Pisani A., Mercuri N.B., and Bernardi G. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci. 19 (1996) 19-24
4. Calabresi P., Centone D., and Bernardi G. Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci. 23 (2000) S57-S63
5. Christopherson K.S., Hillier B.J., Lim W.A., and Bredt D.S. PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J. Biol. Chem. 274 (1999) 27467-27473
6. Coleman P.D., and Yao P.J. Synaptic slaughter in Alzheimer's disease. Neurobiol. Aging 24 (2003) 1023-1027
7. DeKosky S.T., and Scheff S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 27 (1990) 457-464
8. Dunah A.W., and Standaert D.G. Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J. Neurosci. 21 (2001) 5546-5558
9. Dunah A.W., Wang Y., Yasuda R.P., Kameyama K., Huganir R.L., Wolfe B.B., and Standaert D.G. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol. Pharmacol. 57 (2000) 342-352
10. El-Husseini A.E., Topinka J.R., Lehrer-Graiwer J.E., Firestein B.L., Craven S.E., Aoki C., and Bredt D.S. Ion channel clustering by membrane-associated guanylate kinases. Differential regulation by N-terminal lipid and metal binding motifs. J. Biol. Chem. 275 (2000) 23904-23910
11. Elias G.M., and Nicoll R.A. Synaptic trafficking of glutamate receptors by MAGUK scaffolding proteins. Trends Cell Biol. 17 (2007) 343-352
12. Gardoni F., Picconi B., Ghiglieri V., Polli F., Bagetta V., Bernardi G., Cattabeni F., Di Luca M., and Calabresi P. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J. Neurosci. 26 (2006) 2914-2922
13. Garry E.M., Moss A., Delaney A., O'Neill F., Blakemore J., Bowen J., Husi H., Mitchell R., Grant S.G., and Fleetwood-Walker S.M. Neuropathic sensitization of behavioral reflexes and spinal NMDA receptor/CaM kinase II interactions are disrupted in PSD-95 mutant mice. Curr. Biol. 13 (2003) 321-328
14. Gylys K.H., Fein J.A., Yang F., Wiley D.J., Miller C.A., and Cole G.M. Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am. J. Pathol. 165 (2004) 1809-1817
15. Harigaya Y., Shoji M., Shirao T., and Hirai S. Disappearance of actin binding protein, drebrin, from hippocampal synapses in Alzheimer's disease. J. Neurosci. Res. 43 (1996) 87-92
16. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A., and Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 3228-3233
17. Ingham C.A., Hood S.H., Taggart P., and Arbuthnott G.W. Plasticity of synapses in the rat neostriatum after unilateral lesion of the nigrostriatal dopaminergic pathway. J. Neurosci. 18 (1998) 4732-4743
18. Jarabek B.R., Yasuda R.P., and Wolfe B.B. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain 127 (2004) 505-516
19. Kemp J.A., and McKernan R.M. NMDA receptor pathways as drug targets. Nat. Neurosci. 5 (2002) 1039-1042
20. Kennedy M.B. Signal-processing machines at the postsynaptic density. Science 290 (2000) 750-754
21. Kim E., and Sheng M. PDZ domain proteins of synapses. Nat. Rev. Neurosci. 5 (2004) 771-781
22. Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y., Viola K.L., Lambert M.P., Velasco P.T., Bigio E.H., Finch C.E., Krafft G.A., and Klein W.L. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 24 (2004) 10191-10200
23. Lau C.G., and Zukin R.S. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat. Rev. Neurosci. 8 (2007) 413-426
24. Lipton S.A. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr. Alzheimer Res. 2 (2005) 155-165
25. Luthi-Carter R., Apostol B.L., Dunah A.W., DeJohn M.M., Farrell L.A., Bates G.P., Young A.B., Standaert D.G., Thompson L.M., and Cha J.H. Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation. Neurobiol. Dis. 14 (2003) 624-636
26. Lynch D.R., and Guttmann R.P. Excitotoxicity: perspectives based on N-methyl-D-aspartate receptor subtypes. J. Pharmacol. Exp. Ther. 300 (2002) 717-723
27. Marcello E., Gardoni F., Mauceri D., Romorini S., Jeromin A., Epis R., Borroni B., Cattabeni F., Sala C., Padovani A., and Di Luca M. Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity. J. Neurosci. 27 (2007) 1682-1691
28. Mauceri D., Cattabeni F., Di Luca M., and Gardoni F. Calcium/calmodulin-dependent protein kinase II phosphorylation drives synapse-associated protein 97 into spines. J. Biol. Chem. 279 (2004) 23813-23821
29. Mauceri D., Gardoni F., Marcello E., and Di Luca M. Dual role of CaMKII-dependent SAP97 phosphorylation in mediating trafficking and insertion of NMDA receptor subunit NR2A. J. Neurochem. 100 (2007) 1032-1046
30. Menegoz M., Lau L.F., Herve D., Huganir R.L., and Girault J.A. Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OHdopamine lesions. NeuroReport 7 (1995) 125-128
31. Nash J.E., Johnston G.L., Collingridge G.L., Garner C.C., and Brotchie J.M. Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia. FASEB J. 19 (2005) 583-585
32. Niethammer M., Kim E., and Sheng M. Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases. J. Neurosci. 16 (1996) 2157-2163
33. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., and LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39 (2003) 409-421
34. Palop J.J., Jones B., Kekonius L., Chin J., Yu G.Q., Raber J., Masliah E., and Mucke L. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 9572-9577
35. Papa S.M., and Chase T.N. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann. Neurol. 39 (1996) 574-578
36. Picconi B., Gardoni F., Centonze D., Mauceri D., Cenci M.A., Bernardi G., Calabresi P., and Di Luca M. Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J. Neurosci. 24 (2004) 5283-5291
37. Rumbaugh G., Sia G.M., Garner C.C., and Huganir R.L. Synapse-associated protein-97 isoform-specific regulation of surface AMPA receptors and synaptic function in cultured neurons. J. Neurosci. 23 (2003) 4567-4576
38. Sans N., Prybylowski K., Petralia R.S., Chang K., Wang Y.X., Racca C., Vicini S., and Wenthold R.J. NMDA receptor trafficking through an interaction between PDZ. proteins and the exocyst complex. Nat. Cell. Biol. 5 (2003) 520-530
39. Sattler R., and Tymianski M. Molecular mechanisms of glutamate receptormediated excitotoxic neuronal cell death. Mol. Neurobiol. 24 (2001) 107-129
40. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 298 (2002) 789-791
41. Shim K.S., and Lubec G. Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci. Lett. 324 (2002) 209-212
42. Sun Y., Savanenin A., Reddy P.H., and Liu Y.F. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276 (2001) 24713-24718
43. Takagi N., Cheung H.H., Bissoon N., Teves L., Wallace M.C., and Gurd J.W. The effect of transient global ischemia on the interaction of Src and Fyn with the N-methyl-D-aspartate receptor and postsynaptic densities: possible involvement of Src homology 2 domains. J. Cereb. Blood Flow Metab. 19 (1999) 880-888
44. Tao Y.X., and Raja S.N. Are synaptic MAGUK proteins involved in chronic pain?. Trends Pharmacol. Sci. 25 (2004) 397-400
45. Tao Y.X., Rumbaugh G., Wang G.D., Petralia R.S., Zhao C., Kauer F.W., Tao F., Zhuo M., Wenthold R.J., Raja S.N., Huganir R.L., Bredt D.S., and Johns R.A. Impaired NMDA receptor-mediated postsynaptic function and blunted NMDA receptor-dependent persistent pain in mice lacking postsynaptic density-93 protein. J. Neurosci. 23 (2003) 6703-6712
46. Ulas J., and Cotman C. Dopaminergic denervation of striatum results in elevated expression of NR2A subunit. NeuroReport 7 (1996) 1789-1793
47. Vila M., Marin C., Ruberg M., Jimenezs A., Raisman-Vozari R., Agid Y., Tolosa E., and Hirsch E.C. Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia. J. Neurochem. 73 (1999) 344-352
48. Wakabayashi K., Narisawa-Saito M., Iwakura Y., Arai T., Ikeda K., Takahashi H., and Nawa H. Phenotypic down-regulation of glutamate receptor subunit GluR1 in Alzheimer's disease. Neurobiol. Aging 20 (1999) 287-295
49. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
50. Wang H.W., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., Viola K.L., Klein W.L., Stine W.B., Krafft G.A., and Trommer B.L. Soluble oligomers of beta amyloid (1- 42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924 (2002) 133-140